5Whitehouse C, Solomon E. Current status of the molecular character- ization of the ovarian cancer antigen CA125 and implications for its use in clinical screening [ J ]. Gynecologic Oncology, 2003,88 : 152 - 157.
6Duffand F,Therasse P. New guidelines to evalaute the response to treatment in solid tumors [ J ]. Journal of the National Cancer Institu- te ,2000,92:205 - 216.
7Randall TC, Stephen C. Surgical management of ovarian cancer [ J]. Seminars in Surgical Ontology, 1999,17 (3) : 173.
8Hoskins WJ,Mcguire W'P,Brady MF,et al. The effect of diameter of largest residual disease on survival after primary eytoreduetive sur- gery in patients with suboptimal residual epithelial ovarian carcino- ma[J]. American Journal of Obstetrics and Gynecology, 1994,170 (4) : 974 -979.
9Robert E, Brislow MD. Secondary surgical cytoreductive for ad- vanced epithelial ovarian cancer[ J]. Canaer, 1996,78:2049.
10Bristow RE, Chi DS. Platinum - based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta - analysis [ J ]. Gynecologic Oncology, 2006, 103 ( 3 ) : 1070 - 1076.
